Bevacizumab for Newly Diagnosed Glioblastoma: Should You Add Anti-Angiogenic Therapy?
You have just been diagnosed with glioblastoma. Your oncologist is recommending the standard treatment - surgery, six weeks of radiation with daily temozolomide, then six more months of temozolomide. Your team may also suggest adding bevacizumab, a drug that blocks tumor blood vessel growth. Whether to add it is a real question with no single right answer. The evidence on bevacizumab in newly diagnosed GBM is mixed, and your decision should depend on your specific situation.
This article explains what bevacizumab does, what the two largest studies found, which patients might benefit, and questions to ask your team.
What Is Bevacizumab and Why Is It Used in Brain Tumors?
Bevacizumab (brand name Avastin) is a monoclonal antibody, or lab-engineered protein. It blocks a specific target in the body called VEGF (vascular endothelial growth factor). This is a chemical signal that tumors produce to trigger the growth of new blood vessels. This vessel-building process is called angiogenesis. Glioblastoma needs angiogenesis to grow.
Glioblastoma has more blood vessels than almost any other solid tumor. The tumor uses VEGF to build a thick, leaky network of vessels that feeds rapid growth. These leaky vessels also cause fluid buildup (edema), which puts pressure on surrounding brain tissue. This pressure causes many of the neurological symptoms you experience.
When bevacizumab blocks VEGF, it stops the tumor's vessel-building signal. Blood vessels shrink or return to normal size. Edema often decreases significantly, sometimes within days. Studies confirm that this treatment produces rapid, visible tumor control and meaningful reductions in brain swelling. However, the longer-term effects are more complicated.
What Does Standard First-Line Treatment Already Include?
To understand whether to add bevacizumab, you need to know what standard treatment includes. The Stupp protocol, the backbone of first-line GBM treatment since 2005, has three stages:
Maximal safe surgical resection to remove as much tumor as possible
Six weeks of radiation therapy delivered alongside daily low-dose temozolomide chemotherapy
Six months of higher-dose temozolomide, taken in five-day cycles each month
The original Stupp protocol trial showed a median overall survival of 14.6 months. Many centers also offer Tumor Treating Fields (TTFields), a wearable device that delivers low-intensity electric fields, as a fourth component during chemotherapy. For more on how TTFields works, see our article on Tumor Treating Fields (Optune) for Glioblastoma.
The question is whether adding bevacizumab to this intensive treatment improves outcomes.
What Did the Two Major Bevacizumab Trials Actually Show?
Two large, randomized phase III trials tested whether adding bevacizumab to standard temozolomide and radiation helps patients with newly diagnosed GBM. Both trials used the same design. Patients received either bevacizumab or placebo with the Stupp protocol. Researchers measured how long until the tumor grew and how long patients survived.
AVAglio and RTOG 0825: Key Results Compared
Trial Patients Median PFS (bevacizumab vs placebo) Overall Survival Quality of Life AVAglio 921 patients, 23 countries 10.6 vs 6.2 months (HR 0.64) No significant difference Maintained in bevacizumab group RTOG 0825 637 patients, US sites 10.7 vs 7.3 months (HR 0.79) No significant difference Declined in bevacizumab group
The pattern was clear in both trials. Bevacizumab extended progression-free survival (PFS, or the time before the tumor grew on MRI) by about four months. But bevacizumab did not extend overall survival. Patients on bevacizumab did not live longer than patients on placebo. A 2019 review of multiple trials confirmed this pattern: bevacizumab delayed tumor growth but did not extend survival.
Quality of life results differed between the two trials. This matters when you choose a treatment that does not extend survival. In RTOG 0825, patients on bevacizumab reported worse quality of life than patients on placebo. In AVAglio, patients' quality of life stayed the same or improved. This difference may reflect how each trial measured symptoms and managed steroids differently.
Does Bevacizumab Benefit Any Specific GBM Subgroup?
This is the most important question. The answer is: possibly, but not strong enough to recommend as standard treatment for any clear patient group.
Researchers looked at a subgroup of AVAglio patients with a specific GBM type (called proneural) to see if bevacizumab helped them survive longer. This analysis appeared in the Journal of Clinical Oncology and found that proneural tumors might respond better to bevacizumab. However, this finding was based on looking back at trial results. It wasn't planned ahead of time, so it needs to be confirmed in future studies before doctors can use it to make treatment choices.
MGMT methylation (a genetic marker that shows how well temozolomide works) has also been studied to see if it affects bevacizumab response. A review of studies examined bevacizumab combined with temozolomide and radiation for GBM patients with different MGMT statuses. It found that bevacizumab delayed tumor growth in both groups but did not improve overall survival in either group for newly diagnosed patients. MGMT status remains critical for your treatment plan, especially for predicting how well temozolomide will work. If you haven't had molecular testing yet, our article on why this matters in the first 6 weeks after GBM surgery explains why it's important.
Where Bevacizumab Has a Clearer Role: Controlling Edema and Reducing Steroids
Bevacizumab doesn't improve overall survival for newly diagnosed patients. But it does consistently reduce brain swelling, which can really help some patients.
Many GBM patients need dexamethasone (a corticosteroid) to manage the fluid buildup around their tumor. Long-term steroid use causes problems: higher blood sugar, weight gain, muscle weakness, lower immunity, and mood changes. One study found that bevacizumab reduced brain swelling and let many patients lower their steroid doses within weeks.
If your symptoms come mainly from swelling (not from the tumor itself) or if steroids are giving you bad side effects, reducing the swelling could really improve your daily life, even though it won't change how long you survive. This is one of the best reasons to consider bevacizumab for some newly diagnosed patients.
Why Doesn't Bevacizumab Improve Overall Survival?
Scientists have looked for the answer to this puzzle: scans show smaller tumors, but people don't live longer. Three main reasons might explain this.
First, blocking blood vessel growth might make GBM cells spread differently. Instead of growing as a lump, tumor cells spread along existing brain structures. This is harder to see on MRI and harder to treat.
Second, bevacizumab makes tumor blood vessels less leaky. This changes how the tumor looks on MRI. Sometimes the tumor appears smaller even though it hasn't actually shrunk. This is called pseudoresponse. It can give false hope before the tumor comes back, often quickly.
Third, tumors become resistant to bevacizumab over time. They find new ways to build blood vessels, bypassing the VEGF path that bevacizumab blocks. When this happens, the tumor often grows back fast and strong.
Side Effects and Risks to Know Before Starting
Bevacizumab has different side effects than temozolomide and radiation. Before you add it to your treatment, you and your care team should know about these specific risks:
High blood pressure (hypertension): One of the most common side effects. Usually you can control it with medicine, but your doctor needs to check it at every visit.
Blood clots: Blood clots can form in arteries (like a stroke) or veins (like deep vein thrombosis). Tell your doctor if you've had blood clots before.
Impaired wound healing: Bevacizumab interferes with wound healing. Your doctor usually won't start it soon after brain surgery. They'll consider when your surgery was.
Proteinuria (protein in the urine): A sign of kidney stress. Your doctor checks for this with regular urine tests.
Gastrointestinal perforation: Rare but serious. It's more likely if you already have stomach or intestine problems.
Fatigue: Adds to the tiredness you already feel from radiation and chemo.
These risks are serious. If you had recent brain surgery, have high blood pressure that's hard to control, have had blood clots, or have heart problems, bevacizumab might not be right for you.
Where Does Bevacizumab Stand in Current Guidelines?
The FDA approved bevacizumab for recurrent GBM in 2009 after studies showed it could shrink tumors and slow growth in patients whose cancer came back. Doctors do not currently use bevacizumab as standard treatment for newly diagnosed GBM. The two main trials didn't show that bevacizumab extended survival. That's what doctors and health organizations need to see before adding a drug to standard treatment.
Some experienced brain tumor doctors may still use bevacizumab for newly diagnosed patients, mainly those with serious swelling, steroid dependence, or special medical issues. If your team recommends bevacizumab as part of initial treatment, ask why they think it will help you. Getting a second opinion from a major brain tumor center can help you decide if bevacizumab makes sense for you. Our guide on what to do in the first 30 days after a GBM diagnosis walks through how to build that kind of expert review strategy in the time you have.
Questions to Ask Your Oncologist Before Deciding
Are you recommending bevacizumab as a first-line addition, or holding it in reserve for recurrence?
What specific benefit do you expect in my case - edema control, progression delay, or a clinical trial rationale?
Does my MGMT methylation status or GBM molecular subtype support adding bevacizumab upfront?
If I start bevacizumab now and my tumor recurs, how does that change my options at recurrence?
What monitoring will bevacizumab require, and how does that affect my schedule during radiation?
Is there a clinical trial combining bevacizumab with a newer agent that might be worth considering instead?
When to Talk to Your Doctor
Talk to your neuro-oncologist before deciding whether to use bevacizumab as part of your treatment. This conversation is most important if any of these apply: your tumor is causing major swelling, steroids are causing you bad side effects, your team is recommending bevacizumab upfront, or you haven't had molecular testing yet. If you want an expert review of your MRI and pathology reports before starting treatment, you can upload them for a video consultation through HealthUnwired, usually within 48 hours.
This article is general information. Talk to your doctor or care team about your specific situation.